With cancer, time matters.

Designated an FDA Breakthrough Therapy for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (CIS), the novel immunotherapy ANKTIVA® activates key killer cells of the body’s natural immune system to attack the bladder cancer, leading to a long-duration of complete response that for some patients exceeds 47 months.¹

For Healthcare Professionals:
Contact a Representative

For Patients:
Learn more about ANKTIVA®

ANKTIVA is a potent immunostimulant that unlocks anti-tumor activity and promotes a durable, complete response.

ANKTIVA works by activating the body’s natural immune system to fight disease and provide long-term immune memory against the cancer.

Duration of Complete Response

47+ MONTHS AND ONGOING ¹

Maintenance Therapy

3 YEARS ¹

1. ANKTIVA Package insert. lmmunityBio, Inc., 2024; Represents the upper limit of the range of duration of response.

The Power of ANKTIVA

ANKTIVA is an IL-15 receptor alpha that generates IL-15-activated NK, Killer T, and Memory T Cells while avoiding T-reg stimulation

Safety
& Tolerability

Well Tolerated^1,2,3

Treatment-Related AE Deaths 0%^1,2,7

Side Effects Consistent with BCG^2,4,5

Intravesical
Administration

Maintenance Doses in Responders 3 YEARS¹

Efficacy
Profile

Complete Response^1,2

62%	71%
N=77¹ (FDA Efficacy Population)	N=82² (Data from QUILT 3.032 study investigators as published in NEJM Evidence)

% of Responders Who Were Cysectomy Free at 24 Months² 89.2%

(Data from QUILT 3.032 study investigators as published in NEJM Evidence)

Overall Survival at 24 Months² 94%

(Data from QUILT 3.032 study investigators as published in NEJM Evidence)

Duration
of Response

Range of DoR¹ 47+ Month
& Ongoing

(Represents the upper limit of the range of duration of response)

% with duration ≥12 months¹ 58%

(Exceeds IBCG Recommendations⁸)

% with duration ≥24 months¹ 40%

1. ANKTIVA Package insert. lmmunityBio, Inc., ; 2024. 2. Chamie K, et al. IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. NEJM Evid. 2023 Jan;2(1): EVIDoa2200167. doi: 10.1056/EVIDoa2200167. 3. Suderman J, et al. Re: IL-15 Superagonist NAI in BCG Unresponsive Non-muscle-invasive Bladder Cancer. Eur Ural. 2023 Jun;83(6):581. doi: 10.1016/j.eururo. 2023.01.009. 4. BCG Package insert. Merck & Co., Inc. ; 2022. 5. Chamie K, et al. Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin Unresponsive Nonmuscle-lnvasive Bladder Cancer. Ural Pract. 2024 Mar;11(2):367-375. doi: 10.1097/UPJ.0000000000000517. 6. Han KP, et al.. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. 2011 Dec;56(3):804-10. doi: 10.1016/j.cyto.2011.09.028. 7. One death reported due to a cardiac arrest that was unrelated to N-803 + BCG. 8. Kamat AM, Sylvester RJ, Bbhle A, Palau J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oneel. 2016 Jun 1;34(16):1935-44. doi: 10.1200/ JCO.2015.64.4070.

Patient Stories

Read about patients who participated in the clinical trials for ANKTIVA.

Irv's Journey

He was first diagnosed with bladder cancer in 2016 when on Thanksgiving day he had very concerning symptoms, including blood in his urine, and several tumors on the interior surface of his bladder were removed by his local urologist, who treated him with BCG, but he failed to respond and the tumors came back. He was afraid he was going to lose his bladder.

Wayne’s Journey

Wayne has lived a rich life that includes his wife, two daughters and three grandkids. He describes himself as someone who “just likes people.”

Physicians’ Journey

Listen to the physicians’ journey with their patients using ANKTIVA.

Indication and Important Safety Information

INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION: For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at www.anktiva.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482)

ANKTIVA^® is a new choice to help conquer
non-muscle invasive bladder cancer.

For more information, please call 1-877-ANKTIVA